Funding for this research was provided by:
Wellcome (grant MR/K021087/1)
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (Vici grant 016.140.657)
Received: 15 April 2020
Accepted: 17 June 2021
First Online: 21 July 2021
: The authors declare the following competing interests: R.H. is affiliated with QVQ Holding BV, a company offering VHH services and VHH-based imaging molecules. T.D.G, E.E., R.H., J.S., and M.S. are co-inventors on a pending EU patent application EP19190047.1, which covers the use of US28-targeting nanobodies for T-cell-mediated killing of HCMV latently infected cells. The remaining authors declare no competing interests.